细胞周期M期基因在未分化甲状腺癌中高度上调
该研究通过检索基因表达综合数据库(GEO),纳入3项高通量基因表达微阵列研究(32例未分化甲状腺癌、69例乳头状甲状腺癌、75例正常甲状腺),在7组比较中鉴定未分化甲状腺癌特异性差异表达基因。共发现259个上调基因和286个下调基因(至少2倍变化),其中36个上调、40个下调(5倍筛选)。有丝分裂细胞周期在全局上调基因集中高度富集(占前上调基因的44%,p值<10-30)。
要点
- 未分化甲状腺癌占甲状腺癌3%但占甲状腺癌死亡近40%,目前无有效疗法。
- 7组比较中鉴定259个上调、286个下调基因(至少2倍变化),5倍筛选后36个上调、40个下调。
- 有丝分裂细胞周期在全局上调基因集中高度富集(44%的前上调基因,p值<10-30)。
核心结论
- 通过聚焦全局改变的基因,鉴定出未分化甲状腺癌中一致改变的生物学过程和通路,数据支持M期细胞周期基因在未分化甲状腺癌中起重要作用,并可能为未来研究提供方向以识别新的治疗靶点。
研究设计与样本
- 检索美国国家生物技术信息中心基因表达综合数据库(GEO)中人类未分化甲状腺癌组织及正常甲状腺和/或乳头状甲状腺癌组织的高通量基因表达微阵列研究,使用7组独立比较鉴定未分化甲状腺癌特异性基因集,并进行生物学功能和通路分析。
- 共纳入3项符合标准的研究,包括32例未分化甲状腺癌患者、69例乳头状甲状腺癌和75例正常组织。
主要发现
- 在7组比较中,未分化甲状腺癌有259个上调基因和286个下调基因(至少2倍变化)。
- 使用5倍筛选,未分化甲状腺癌中36个基因上调,40个基因下调。
- 全局上调前10个基因中,4/10(MMP1、ANLN、CEP55和TFPI2)已知在未分化甲状腺癌进展中起作用,6/10(TMEM158、CXCL5、E2F7、DLGAP5、MME和ASPM)未在未分化甲状腺癌中被特异性涉及。
- 全局下调前10个基因中,3/10(SFTA3、LMO3和C2orf40)在此背景下为新发现,7/10(SLC26A7、TG、TSHR、DUOX2、CDH1、PDE8B和FOXE1)先前已在未分化甲状腺癌中被鉴定。
- 通过未分化甲状腺癌细胞的微阵列分析,实验验证了7个转录因子(KLF16、SP3、ETV6、FOXC1、SP1、EGFR1和MAFK)与未分化甲状腺癌特异性基因的显著相关性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anaplastic thyroid carcinoma (ATC) accounts for only 3% of thyroid cancers, yet strikingly, it accounts for almost 40% of thyroid cancer deaths. Currently, no effective therapies exist. In an effort to identify ATC-specific therapeutic targets, we analyzed global gene expression data from multiple studies to identify ATC-specific dysregulated genes. METHODS: The National Center for Biotechnology Information Gene Expression Omnibus database was searched for high-throughput gene expression microarray studies from human ATC tissue along with normal thyroid and/or papillary thyroid cancer (PTC) tissue. Gene expression levels in ATC were compared with normal thyroid or PTC using seven separate comparisons, and an ATC-specific gene set common in all seven comparisons was identified. We investigated these genes for their biological functions and pathways. RESULTS: There were three studies meeting inclusion criteria, (including 32 ATC patients, 69 PTC, and 75 normal). There were 259 upregulated genes and 286 downregulated genes in ATC with at least two-fold change in all seven comparisons. Using a five-fold filter, 36 genes were upregulated in ATC, while 40 genes were downregulated. Of the 10 top globally upregulated genes in ATC, 4/10 (MMP1, ANLN, CEP55, and TFPI2) are known to play a role in ATC progression; however, 6/10 genes (TMEM158, CXCL5, E2F7, DLGAP5, MME, and ASPM) had not been specifically implicated in ATC. Similarly, 3/10 (SFTA3, LMO3, and C2orf40) of the most globally downregulated genes were novel in this context, while 7/10 genes (SLC26A7, TG, TSHR, DUOX2, CDH1, PDE8B, and FOXE1) have been previously identified in ATC. We experimentally validated a significant correlation for seven transcription factors (KLF16, SP3, ETV6, FOXC1, SP1, EGFR1, and MAFK) with the ATC-specific genes using microarray analysis of ATC cell lines. Ontology clustering of globally altered genes revealed that "mitotic cell cycle" is highly enriched in the globally upregulated gene set (44% of top upregulated genes, p-value <10-30). CONCLUSIONS: By focusing on globally altered genes, we have identified a set of consistently altered biological processes and pathways in ATC. Our data are consistent with an important role for M-phase cell cycle genes in ATC, and may provide direction for future studies to identify novel therapeutic targets for this disease.
引用
- Weinberger P, Ponny SR, Xu H, et al. Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma. Thyroid. 2016. PMID: 27796151. doi:10.1089/thy.2016.0285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。